Relay Therapeutics, Inc.

NASDAQ:RLAY

Biotechnology

Healthcare
$16.51 +2.63%

+$0.41 today

Market cap
$3.65B
Beta
1.75
P/E (TTM)
-10.5
EPS (TTM)
-$1.52
52W Low $3.03High $17.47

Volume 2.43M

Average 3.70M

RLAY Capital Expenditures

Cash spent on property, plant, equipment, and other long-term assets.

Relay Therapeutics, Inc.NASDAQ: RLAY

Capital Expenditures · Q2 FY2026 · quarter ended Jun 2026

Capital expenditures turns positive

Q2 FY2026 capital expenditures was $0, compared with -$26K a year earlier. Trailing-twelve-month capital expenditures was $0. Over 3 fiscal years it compounded at -64.4% a year.

Context

  • Capital expenditures amounted to 2.7% of revenue in FY2025, down 17.5 pp from a year earlier.
  • Capital expenditures grew in size in 0 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly capital expenditures holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$0— QoQ
Last fiscal yearDec 2025
-$410K-79.7% YoY
LTMJun 2026
$0+100.0% YoY
Capital Expenditures past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+100.0%——
1 year-79.7%——
3-year CAGR-64.4%——
5-year CAGR——
10-year CAGR——

Capital Expenditures history

USD · from the cash flow

Latest · FY2025
(410K) USD
Year-over-year change
+79.7%

Capital Expenditures vs competitors

How RLAY compares with its peers on the latest reported figures

  • RLAY's LTM Jun 2026 capital expenditures of $0 is the 10th largest of the 11 companies compared; the peer median is $393K.
  • Its year-over-year change of +100.0% is the highest of 10, against a peer median of -48.1%.
  • Capital expenditures amounts to 0.0% of revenue for RLAY, versus a peer median of 1.0%.
RLAY Competitors Peer median
Capital Expenditures for RLAY and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NRIXNurix Therapeutics, Inc.LTM Aug 2026$9.5M -13.4%+4.6%1.4%
RVMDRevolution Medicines, Inc.LTM Jun 2026$9.1M -41.1%+13.9%—
IDYAIDEAYA Biosciences, Inc.LTM Mar 2026$2.01M -48.1%-11.7%0.9%
KYMRKymera Therapeutics, Inc.LTM Jun 2026$1.19M -37.5%-20.1%1.1%
ORICORIC Pharmaceuticals, Inc.LTM Mar 2026$487K -64.1%-30.0%—
TNGXTango Therapeutics, Inc.LTM Sep 2026$299K -68.5%-48.5%—
TYRATyra Biosciences, Inc.LTM Mar 2026$215K -60.3%-36.8%—
ERASErasca, Inc.LTM Sep 2026$132K +10.9%-80.2%—
PRLDPrelude Therapeutics IncorporatedLTM Mar 2026$20K -96.2%-71.9%0.1%
RLAYRelay Therapeutics, Inc.LTM Jun 2026$0 +100.0%-64.4%0.0%
AVBPArriVent BioPharma, Inc. Common StockLTM Mar 2026$0 ———
Peer median (excluding RLAY) $393K-48.1%-30.0%1.0%

Competitors are the stored peer set for RLAY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(363.87M)(290.51M)(341.97M)(337.71M)(276.48M)
Depreciation & Amortization3.93M4.13M5.27M5.46M3.56M
Deferred Income Tax00000
Stock-Based Compensation48.45M56.14M86.03M94.14M62.42M
Change in Working Capital97.34M11.25M(32.46M)14.62M(23.31M)
Accounts Receivables77.79M97K5.22M00
Inventory00000
Accounts Payables930K1.99M(2.39M)0(11.44M)
Other Working Capital18.62M9.16M(35.28M)14.62M(11.87M)
Other Non-Cash Items139.74M(10.5M)(17.19M)(25.62M)(1.65M)
Operating Cash Flow(74.41M)(229.49M)(300.32M)(249.11M)(235.46M)
Capital Expenditures(3.47M)(9.06M)(4.13M)(2.02M)(410K)
Acquisitions (Net)(25.3M)179.68M000
Purchases of Investments(980.67M)(535.42M)(385.54M)(650.63M)(122.97M)
Sales of Investments529.92M355.74M647.3M611.56M316.18M
Other Investing Activities0(179.68M)000
Investing Cash Flow(479.51M)(188.75M)257.63M(41.08M)192.8M
Debt Repayment00000
Common Stock Issued382.21M284.74M30.28M265.89M1.6M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities5.88M5.17M4.47M4.26M0
Financing Cash Flow388.09M289.91M34.75M270.15M1.6M
Effect of Forex Changes00000
Net Change in Cash(165.83M)(128.33M)(7.93M)(20.04M)(41.05M)
Free Cash Flow(77.88M)(238.55M)(304.44M)(251.13M)(235.87M)

Relay Therapeutics, Inc.

NASDAQ:RLAY

Intrinsic Alpha fair value

Locked

Current Price

$16.51

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.